Zydus Advances Phase II Trial of ZYIL1, a Promising NLRP3 Inhibitor, in ALS Patients
Zydus Life Sciences has received the green light from the Central Drugs Standard Control Organization (CDSCO), India, to embark on ...
Tag: Amyotrophic lateral sclerosis (ALS)
